biOasis Technologies Inc. (the "Company") (TSX VENTURE:BTI) is pleased to
announce the appointment of Dr. Leigh Anderson as a member of the Company's
Scientific Advisory Board. "Dr. Anderson has vast expertise in the area of
diagnostics and biomarkers and their application to human disease and our team
is very excited to have him aboard," Rob Hutchison CEO.


Dr. Anderson is the founder and CEO of the Plasma Proteome Institute ("PPI"),
Washington DC (www.plasmaproteome.org). The Institute aims to foster a
comprehensive exploration of the proteins of human blood plasma (the plasma
proteome) and the application of novel protein measurements in clinical
diagnostics. Prior to founding PPI, Dr. Anderson was Chief Scientific Officer at
Large Scale Biology Corporation (Nasdaq: LSBC), whose proteomics division he
founded in 1985 (as Large Scale Biology) prior to its merger in 1999 with
Biosource Technologies. At LSBC, he developed the first automated
two-dimensional electrophoresis technology platform for proteomics research and
pioneered a range of applications in drug discovery, toxicology and in
identification of surrogate markers for different diseases.


Dr. Anderson currently serves on the Board of Directors of Luna Innovations (a
developer of novel materials and sensors) and was previously a member of the
boards of Dade Behring Holdings (a global diagnostics company) and LSBC. He also
serves on the advisory boards of the UVic-Genome BC Proteomics Centre
(University of Victoria, BC Canada) and Better Biomarkers of Acute and Chronic
Allograft Rejection, a Genome Canada Initiative for Human Health (Vancouver, BC
Canada). Dr Anderson is also on the editorial board of the scientific journal
Molecular and Cellular Proteomics and is a principal of the Anderson Forschung
Group.


Dr. Anderson holds more than 30 patents and has written a book and over 130
scientific publications, mainly in the areas of proteomics and its applications
to biomedicine.


About the Company

biOasis Technologies Inc. is a Canadian Biotechnology company engaged in the
development and commercialization of diagnostics and therapeutics related to
neurological diseases. It has extensive and comprehensive intellectual property
("IP") which it obtained from the University of British Columbia. The Company's
initial area of focus will be on the utilization of the IP to pursue a biomarker
for the diagnosis of Alzheimer's disease. The IP has been corroborated in double
blinded and successive multi-site clinical trials.


According to the Centers for Disease Control and Prevention ("CDC"), Alzheimer's
disease was listed as the "underlying cause of death" for 65,829 Americans in
2004. It was the seventh leading cause of death for people of all ages and the
fifth leading cause of death in people age 65 and older.


To find out more about biOasis Technologies Inc. visit www.bioasis.ca.

On Behalf of the Board of Directors

Robin Hutchison, Director and CEO
Cadillac Ventures (TSXV:CDC)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Cadillac Ventures Charts.
Cadillac Ventures (TSXV:CDC)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Cadillac Ventures Charts.